Colorectal neoplasia prophylaxis

a technology of colon adenocarcinoma and prophylaxis, which is applied in the field of aminoglycoside antibiotics, can solve the problems of increasing the incidence of colon adenocarcinoma, unable to provide the public with any cure for cancer, inflammatory disease, arthritis, etc., and achieves the reduction of the development of colorectal neoplasia, poor gut absorption, and the effect of reducing the development of colorectal

a technology of colon adenocarcinoma and prophylaxis, which is applied in the field of aminoglycoside antibiotics, can solve the problems of increasing the incidence of colon adenocarcinoma, unable to provide the public with any cure for cancer, inflammatory disease, arthritis, etc., and achieves the reduction of the development of colorectal neoplasia, poor gut absorption, and the effect of reducing the development of colorectal

US20050020515A1Inactive Publication Date: 2005-01-27BOARD OF RGT THE UNIV OF TEXAS SYST
2 Cites 12 Cited by

Examples

Experimental program
Comparison scheme
Effect test

examples

[0021] In the following examples, we demonstrate that orally-delivered aminoglycosides reduce development of colorectal neoplasia.

[0022] I. Orally-delivered aminoglycosides reduce development of colon cancer in animal models predisposed to colon neoplasia. Smad3 mutant and APC / MIN mice are fed on a standard laboratory diet, with aminoglycoside antibiotics added to the water. For example, 4 ml neomycin sulfate (BIOSOL, Pharmacia & Upjohn Company) was diluted in 500 ml sterile drinking water to give a final concentration of 1.6 mg / ml neomycin sulfate (1.1 mg / ml neomycin). Metronidazole was diluted in sterile drinking water to a final concentration of 0.5 mg / ml. The same concentrations are used for either combined or separate drug trials.

[0023] Smad3 mutant mice are maintained in 129Sv strain; APC / MIN mice are maintained in C57BL / 6J. Both Smad3 mutant and APC / MIN mice are started on antibiotics at 5 weeks of age (range:4-6 weeks). Mice are monitored and scored for survival and visibl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

Development of colorectal neoplasia in a patient subject or predisposed to colorectal neoplasia is reduced by the steps of (a) determining a patient is subject or predisposed to colorectal neoplasia; and (b) enterically delivering into the gut of the person an effective amount of an aminoglycoside antibiotic having poor gut absorption, whereby the development of the colorectal neoplasia is reduced as compared with otherwise similar non-treated patients.

Description

FIELD OF THE INVENTION [0001] The field of this invention is use of aminoglycoside antibiotics to reduce development of colorectal neoplasia. BACKGROUND OF THE INVENTION [0002] Aminoglycosides are potent bactericidal antibiotics, particularly active against aerobic, gram-negative bacteria and act synergistically against certain gram-positive organisms. Gentamicin is the most commonly used aminoglycoside, but amikacin may be particularly effective against resistant organisms. Aminoglycosides are used in the treatment of severe infections of the abdomen and urinary tract, as well as bacteremia and endocarditis. Aminoglycosides are poorly absorbed from the gastrointestinal tract. After parenteral administration, aminoglycosides are primarily distributed within the extracellular fluid. Penetration of biologic membranes is poor because of the drug's polar structure, and intracellular concentrations are usually low, with the exception of the proximal renal tubule; for review, see, Gonzale...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
27 Jan 2005
Publication
US20050020515A1
IPC
A61K31/7036
CPC
A61K31/7036
Inventors
GRAFF, JONATHAN; WIEDUWILT, MATTHEW